154 related articles for article (PubMed ID: 2328593)
1. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation.
Green TP; Isham-Schopf B; Steinhorn RH; Smith C; Irmiter RJ
Crit Care Med; 1990 May; 18(5):494-8. PubMed ID: 2328593
[TBL] [Abstract][Full Text] [Related]
2. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants.
Urlesberger B; Zobel G; Zenz W; Kuttnig-Haim M; Maurer U; Reiterer F; Riccabona M; Dacar D; Gallisti S; Leschnik B; Muntean W
J Pediatr; 1996 Aug; 129(2):264-8. PubMed ID: 8765625
[TBL] [Abstract][Full Text] [Related]
3. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
[TBL] [Abstract][Full Text] [Related]
4. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
[TBL] [Abstract][Full Text] [Related]
5. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO).
Zavadil DP; Stammers AH; Willett LD; Deptula JJ; Christensen KA; Sydzyik RT
J Extra Corpor Technol; 1998 Jun; 30(2):83-90. PubMed ID: 10182118
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival.
Baird CW; Zurakowski D; Robinson B; Gandhi S; Burdis-Koch L; Tamblyn J; Munoz R; Fortich K; Pigula FA
Ann Thorac Surg; 2007 Mar; 83(3):912-9; discussion 919-20. PubMed ID: 17307433
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients.
Fitousis K; Klasek R; Mason PE; Masud F
Perfusion; 2017 Apr; 32(3):238-244. PubMed ID: 27837164
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation.
Ambrose TM; Parvin CA; Mendeloff E; Luchtman-Jones L
Clin Chem; 2001 May; 47(5):858-66. PubMed ID: 11325889
[TBL] [Abstract][Full Text] [Related]
10. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Krueger K; Schmutz A; Zieger B; Kalbhenn J
Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
[TBL] [Abstract][Full Text] [Related]
11. Procedural variables which affect activated clotting time test results during extracorporeal membrane oxygenation therapy.
Uden DL; Payne NR; Kriesmer P; Cipolle RJ
Crit Care Med; 1989 Oct; 17(10):1048-51. PubMed ID: 2791566
[TBL] [Abstract][Full Text] [Related]
12. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400.
Colby CE; Sheehan A; Benitz W; Van Meurs K; Halamek LP; Moss RL
J Extra Corpor Technol; 2003 Mar; 35(1):35-8. PubMed ID: 12680494
[TBL] [Abstract][Full Text] [Related]
13. Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients.
Mazzeffi MA; Tanaka K; Roberts A; Rector R; Menaker J; Kon Z; Deatrick KB; Kaczorowski D; Griffith B; Herr D
J Cardiothorac Vasc Anesth; 2019 May; 33(5):1216-1220. PubMed ID: 30181084
[TBL] [Abstract][Full Text] [Related]
14. Hemolysis during long-term extracorporeal membrane oxygenation.
Steinhorn RH; Isham-Schopf B; Smith C; Green TP
J Pediatr; 1989 Oct; 115(4):625-30. PubMed ID: 2795361
[TBL] [Abstract][Full Text] [Related]
15. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
16. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
17. Coagulation and anticoagulation in extracorporeal membrane oxygenation.
Muntean W
Artif Organs; 1999 Nov; 23(11):979-83. PubMed ID: 10564301
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation.
Bembea MM; Schwartz JM; Shah N; Colantuoni E; Lehmann CU; Kickler T; Pronovost P; Strouse JJ
ASAIO J; 2013; 59(1):63-8. PubMed ID: 23263338
[TBL] [Abstract][Full Text] [Related]
19. A multistate Kalman filter for neonatal clotting time prediction and early detection of coagulation disturbances.
de Haan AF; van der Velde J; Geven WB; Festen C; Verbeek AL
Methods Inf Med; 1999 Jun; 38(2):113-8. PubMed ID: 10431515
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
